Vivimed Labs has officially entered Corporate Insolvency Resolution Process (CIRP). An invitation for Expressions of Interest (EOI) has been issued, with a deadline of June 29, 2026. The company faces declining revenues and an incomplete audit.

Vivimed Labs Enters Corporate Insolvency Resolution Process

Vivimed Labs has formally entered the Corporate Insolvency Resolution Process (CIRP), a significant development for the company and its stakeholders. An invitation for Expressions of Interest (EOI) has been issued by the Interim Resolution Professional (IRP), T Narayana Swamy, marking the beginning of a structured process to find a resolution for the company.

What just happened

Vivimed Labs is now under CIRP. The IRP has set a timeline for potential investors to express their interest, submit objections, and ultimately present resolution plans.

Why this matters

This signifies a critical phase for Vivimed Labs, as the company seeks a way out of its financial distress. The success of the CIRP process will determine the company's future. Investors should monitor the EOI submissions and the development of resolution plans.

The backstory

Vivimed Labs has experienced a revenue decline, with operations generating ₹103.60 crore in FY 2024-25, down from ₹136.80 crore in FY 2023-24. Revenue for the nine months ended December 31, 2025, was ₹48.23 crore. The company also has a non-operational manufacturing facility in Bidar, Karnataka.

What changes now

The focus shifts to attracting resolution applicants. The IRP will manage the process, evaluating expressions of interest and resolution plans within strict timelines.

Risks to watch

The statutory audit for FY 2026 is ongoing and not finalized, which may present challenges for potential bidders needing complete financial data. The non-operational status of the Bidar facility is another concern.

Peer comparison

While direct peer comparison in CIRP is complex, Vivimed Labs' operational capacity includes significant manufacturing capabilities for tablets (900 million), capsules (580 million), and other formulations.

Context metrics (time-bound)

• Last date for receipt of EOI: June 29, 2026
• Last date for submission of resolution plans: August 28, 2026
• Revenue FY 2023-24: ₹136.80 crore
• Revenue FY 2024-25: ₹103.60 crore

What to track next

Investors should closely follow the EOI process and the submission of resolution plans. The finalization of the FY 2026 audit will also be a key point to watch.